Investors
Quarterly Reports
Q2 2020 Report
Tuesday, 18 AugustOnlineA presentation by BerGenBio’s senior management team will take place Tuesday 18 August at 10:00 am CET:
Webcast link: https://channel.royalcast.com/webcast/hegnarmedia/20200818_6/
Dial-in numbers:
NO: +47-21-956342
SE: +46-4-0682-0620
DK: +45 78768490
UK: +44-203-7696819
US: +1 646-787-0157
Pin: 712491
Link to live webcastCorporate Presentation
H. C. Wainwright 22nd Annual Global Investment Conference
14 - 16 September 2020
Read More
Annual Report 2019
BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers.
Our annual report
Jonas Lies vei 91, 5009 Bergen, Norway
+ 47 559 61 159